Stargazer Pharmaceuticals, Inc. — Form D/A
Stargazer Pharmaceuticals, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2020-05-13. The offering totals $62.2M, of which $28.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-05-13
- Form: D/A
- Accession: 0001737396-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $62.2M
- Amount sold: $28.5M
- Remaining: $33.7M
- Investors: 9
- Date of first sale: 2018-04-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-310231
Issuer
- Name: Stargazer Pharmaceuticals, Inc.
- CIK: 0001737396
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 200 CLARENDON STREET, BOSTON, MA, 02116
- Phone: 5109138357
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Daniel Curran | Director | Waltham, MA |
| Richard Gaster | Director | Waltham, MA |
| Wende Hutton | Director | Menlo Park, CA |
| Nanna Luneborg | Director | San Diego, CA |
| Iyona Rajkomar | Director | Mendham, NJ |
| Gary Sternberg | Director | Boston, MA |
| John Wagner | Director | LOS ANGELES, CA |
| Gary Sternberg | Executive Officer | Boston, MA |
| Martin Edwards | Director | Boston, MA |
Other filings by this issuer (1)
More